Member Info for Ahfam3

What suprises me and I think a few have mentioned it before maybe Thoth as well. Is no proactive interview for over a year even with that has happened let alone the HNWI's multiple investments.

You would have thought Dr Mitchell would be elated to mention we are cashed up for ph1. It's almost as if they are unavailable for comment.

Patience Silver, you've been here long enough to know we are in the process of manufacturing a covid pill. Nothing has changed are still superior to dex and bari (as bari has tox issues) and the nothing has failed or been pulled.

We are on the verge of taking Tyk2 100% owned into ph1 if the majors allow us to and based on pre-clinical data with no tox or mtd issues we should ace it and that will double if not treble the value of Tyk2 1801.
Then we have 1802 double world-wide patented and an additional euro grant in T-All granted just recently.

So the ball is in the majors courts they have expiring patents, pipelines and reducing income streams. We on the other hand have £6.5m+ to take Tyk2 1801 through ph1 and are being backed by some HNWI's who have £20m+ minimum in liquid assets and who will want to see a superior return on their investment not a 5 or 10bag but 50 to 100 bag.
The question is will the majors allow us to go to phase 1 or will they licence or even takeout pre-clinical.

Many happy returns chaps- some have waited over 8yrs+ so another 3months+ is not a problem for a once in a lifetime company.

Citizen here's my amatuer research-
https://immunityageing.biomedcentral.com/articles/10.1186/s12979-022-00271-2

Received
30 December 2021
Accepted
11 February 2022
Published
05 March 2022

We know that the WHO also recommends IL-6 againt covid (https://www.who.int/news/item/06-07-2021-who-recommends-life-saving-interleukin-6-receptor-blockers-for-covid-19-and-urges-producers-to-join-efforts-to-rapidly-increase-access) and more recently (https://news.un.org/en/story/2022/01/1109722)- we also know that our Tyk2 inhibits IL-6 from both the US Army Lupus research and the general slides from prev. Investor meet presentations.

Many happy returns chaps- the silence is takeout type defeaning.

Thank you Sad for taking the time to post some excellent insight and research.
Very exciting to think GSK would be eager to get Chk1 moving or even apply for a orphan fast-track. I believe anogenital was the indication a fast-track was touted for.

Certainly has all the hallmarks of a takeover.

Question is what price will they offer £30-50 would be my dream, but I have a terrible feeling they will go with a low ball £20. That said we have Dr Michael Owen on board and he knows a thing or two about takeovers and approriate values of just a coincidence we bought him and Dr Birch on board prior to extra patent grants and gearing up Tyk2 into both auto-immune and cancer indications.

I have every confidence that if a low ball of £20 did come in it would be swiftly sent back.

Either way many happy returns chaps- certainly seems the silence before the storm.

That was excellent research Citizen- Uberc..wombles at work ready for the impeding onslaught as they arrive in droves soon, we are getting ever closer to newsflow and cta of course.

Mega exciting isn't it Num4, most have waited a long time for Sareum to take something 100% owned to trials and here we are on the cusp of it.

Will it happen or will a major take us out to avoid the risk of us aceing ph1 and trebling the price.

Many happy returns chaps- as Num4 point out just a couple months to wait and most have waited years so daily, weekly swings in price are the normal order but we're certainly better placed than most at present.

Absolutely Cobra- grover woof doesn't seem to grasp it.

I'm very well Thank you, I share he same sentiments

Nice to see you posting again Andy- calm before the chaos positive of course never known it to be so tense. Personally I would like to see another patent grant (secret of course) and cta for 1801 but half expecting a licencing deal or announcement of takeout.

Excellent research and insight chaps.
Looking ever the more likely momo is a smoke screen.

It was the spawn of the uberc..wombles expect more like it soon.

We are in the period now where we should start to get newsflow. Also as someone mentioned it seems to be takeover season over in the US and we have patented compounds of interest in the fields those takeovers are happening.

Many happy returns chaps- My hunch is we'll get more but signifcant patent protection this month and possibly cta or signal towards an indication for Tyk2 auto-immune. It's been eerily quiet of late not even a tweet and share price movement has been almost non-existent.

Good game chaps- keep the f.. on their toes. They we know that Chk1 is a gamechanger in the industry.
80%+ tumour reduction is phenominal and they know it- we have 2 Tyk2's which will be equally if not better in their respective markets 100% owned and patented to the hilt, then their is the goose that lays the golden eggs namely The SKIL Platform which we cannot even begin to imagine what the value of will be.

Many happy returns chaps. Endgame or CTA ph1 then end game but it's too hot to risk it to ph1 in my opinion as the majors are under the cosh with expiring patents and revenues so wouldn't want to risk paying 4 to 10x dependant on results to what they could now.

Thank you working, we're looking to disrupt a standard of care of 50yrs.

All patented, no tox or mtd, a once in a lifetime company- roll on CTA.

And there is our little beauty IL-6 again which in my opinion Dr Reader is going for the mother of all patents i.e. all respiritory including bacterial pneumonia.

https://uspto.report/patent/app/20210087154

Seen as a life saver by the World Health Organisation-

https://www.who.int/news/item/06-07-2021-who-recommends-life-saving-interleukin-6-receptor-blockers-for-covid-19-and-urges-producers-to-join-efforts-to-rapidly-increase-access

This was July 2020- we have since had it tweaked to perfection more patents. It's safer with no tox issues insofar and no mtd so higher doses can be given.
Many happy returns chaps, all roads seem to be leading to safer and more effective therapy and our genius Dr Reader knew it and applied for the patents whilst everyone was chasing covid money-

Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, is pleased to announce that encouraging results have been published for its small molecule dual tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1) inhibitors in disease model studies of systemic lupus erythematosus (SLE) by its collaborator, SRI International.

These studies were supported by a research grant from the US Department of Defense (DoD) and the report was recently published on the website of the Defense Technical Information Center (https://apps.dtic.mil/sti/citations/AD1087498).

The authors concluded that an approach using selective TYK2/JAK1 inhibitors may lead to the development of a therapy for lupus that does not involve the harmful side effects of systemic immune system suppression and may benefit numerous lupus patients in need of new options. They also noted that the results could influence treatments of other autoimmune diseases such as arthritis and psoriasis.

Specifically, it was reported that treatment with TYK2/JAK1 inhibitor SAR-20351 (now known as SDC-1802) reduces autoantibodies (biological markers of lupus severity) in a spontaneous mouse model of SLE. The data also provided evidence that SAR-20351 inhibits cytokines that play a critical role in lupus, including interferon-alpha, IL-6 and IL-23. The inhibition of IL-23 signalling by SAR-20351 may play a role in the decrease of autoantibodies in the lupus mouse model, as IL-23 signalling drives the differentiation of Th17 cells, which leads to autoantibody production and are pathogenic in lupus.

IL-6 which our Tyk2 inhibts gets a mention. Thoth was taking about zoonotic diseases as far back as 2020 I believe if not earlier.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4129056/

https://bmcmedgenet.biomedcentral.com/articles/10.1186/s12881-020-01006-0

As always with our Tyk2's we are sitting on a enormous goldmine of epic proportions.

Many happy returns chaps.

- No change in the science,
- More and more validation for Tyk2 and patent protection upon patent protection,
- £6m+ from HNWI within 6 months maybe attributed to capsule formulation in covid, all respiritory illnesses (if you view the patent) but equally maybe tyk2 1802 as mention also in the RNS's relating to each investment.
- Also as per covid research update bacterial pneumonia was also given a crack at and no doubt will be again.
- Above all nothing has failed in the last 10yrs+
- In regards chk1- no better validation than cancer research going out of their way to shout about combo therapy and we've seen the slides on tumour reduction- the Gsk deal is just further validation of it.

We are approaching end June and it's nearly CTA time hence the emergence of grover woof and no doubt a few other c..wombles will ensue.

Many happy returns chaps.

Chk1 was accepted for cta in 5 Apr 2016, Royal Marsden chosen and trial start announced on 23 May to begin on 31 May and licence came in from Pronai on 27 Sept 2016.

On a side note, didn't Thoth mention Tyk2 as topical for hair regrowth